Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-02-18
2011-11-08
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
08053409
ABSTRACT:
The present invention is intended to provide a novel pharmaceutical agent having an excellent preventive effect on post-stroke RSD. The present invention provides an agent for preventing the onset of post-stroke RSD, comprising natural calcitonin or a calcitonin derivative as an active ingredient. The present invention is also intended to provide a method for preventing the onset of post-stroke RSD, comprising administering natural calcitonin or a calcitonin derivative and use of natural calcitonin or a calcitonin derivative for producing an agent for preventing the onset of post-stroke RSD.
REFERENCES:
patent: 2007/0015702 (2007-01-01), Ito et al.
Appelboom, T., “Calcitonin in Reflex Sympathetic Dystrophy Syndrome and Other Painful Conditions,” Bone, vol. 30, No. 5, Supplement, pp. 84S-86S, May 2002.
Australian Office Action dated Apr. 30, 2010 for Australian Application No. 2007301170.
Braus et al., “The shoulder-hand syndrome after stoke: a prospective clinical trial”, Ann. Neruol., vol. 36, 1994, pp. 728-733.
Buckle, R., “P18. The Effect of Calcitonin in Sudeck's Atrophy,” Abstracts from the Bone and Tooth Society Meeting, p. 480, Apr. 1989.
Canadian Application No. 2,664,300, Office Action, Oct. 7, 2010, pp. 1-3.
Casale et al., “Increased sympathetic tone in the left arm of patients affected by symptomatic myocardial ischemia”, Functional Neruology, vol. 4, 1989, pp. 161-163.
Daoudi et al., “A comparative study of two calcitonins in the prevention of post-traumatic reflex sympathetic dystrophy”, J. Pharm. Clin., vol. 11, 1992, pp. 95-100.
Daviet et al., “Clinical factors in the prognosis of complex regional pain syndrome type I after stroke: a prospective study”, Am. J. Phys. Med. Rehabil., vol. 81, 2002, pp. 34-39.
Gobelet et al., “The Effect of Adding Calcitonin to Physical Treatment on Reflex Sympathetic Dystrophy,” Pain, vol. 48, pp. 171-175, 1992.
Hamamci et al., “Calcitonin Treatment in Reflex Sympathetic Dystrophy: A Preliminary Study,” British Journal of Clinical Practice, vol. 50, No. 7, Oct./Nov. 1996, pp. 373-375.
Ide et al., “Pathological condition and treatment for reflex sympathetic dystrophy—focusing on shoulder-hand syndrome”, J. Jpn. Orthop. Assoc., vol. 69, Nos. 2 & 3, 1995.
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Apr. 9, 2009 for International Application No. PCT/JP2007/068618.
Kissling et al., “Prevention of recurrence of Sudeck's disease with calcitonin”, Rev. Chir. Orthop. Reparatrice Appar. Mot., vol. 77, 1991, pp. 562-567.
Kondo et al., “Protocol to prevent shoulder-hand syndrome after stroke”, Arch. Phys. Med. Rehabil., vol. 82, 2001, pp. 1619-1623.
Korean Application No. 10-2008-7031433; Korean Office Action; Dec. 3, 2010; pp. 1-5.
Marx et al., “Preventing recurrence of reflex sympathetic dystrophy in patients requiring an operative intervention at the site of dystrophy after surgery”, Clin. Rheumatol., vol. 20, 2001, pp. 114-118.
Partial English Translation of the Relevant Parts of Yamaga et al., “Nosocchu Henmahi ni Tomonau Itami Katate Shokogun” (Special edition, Pain Accompanying Post-Stroke Hemiplegia—Shoulder-hand Syndrome), Journal of Pain and Clinical Medicine, vol. 4, No. 2, pp. 115-122, 2004.
Phillippe Gallien et al., “The reflex sympathetic dystrophy syndrome in patients who have had a spinal cord injury,” Paraplegia, vol. 33, Dec. 1995, pp. 715-720.
Quatraro, “Calcitonin in painful diabetic neuropathy”, Lancet, vol. 339, 1992, pp. 746-747.
R. Nuti et al., “Carbocalcitonin Treatment in Sudeck's Atrophy,” Clinical Orthop., No. 215, Feb. 1987, pp. 217-222.
Riou et al., “Can algodystrophy be prevented by thyrocalcitonin?”, Rev. Chir. Orthop. Reparatrice Appar. Mot., vol. 77, 1991, pp. 208-210.
Siligardi et al., Correlations between biological activities and conformational properties for human, salmon, eel, porcine calcitonins and Elcatonin elucidated by CD spectroscopy. Eur J Biochem. May 1, 1994;221(3):1117-25.
Terayama, “Apporach to the pain in orthopedics 5 Shoulder Pain”, 1998, pp. 183-197.
Wade et al., “A critical review of controlled clinical trials for peripheral neruopathic pain and complex regional pain syndromes”, Pain, USA, vol. 73, 1997, pp. 123-139.
Yamaga et al., “Special edition, diagnosis and treatment of reflex sympathetic dystrophy (RSD) Drug therapy for reflex sympathetic dystrophy (RSD)—Calcitonin treatment as main therapy”, vol. 9, 1996, pp. 1191-1198.
Yamaga et al., “Special edition, pain accompanying post-stroke hemiplegia Shoulder-hand syndrome”, vol. 4, No. 2, 2004, pp. 115-122.
Yamaga et al., “Special edition, reflex sympathetic dystrophy Treatment for reflex sympathetic dystrophy—from an orthopedic perspective”, vol. 54, 2001, pp. 306-314.
Zollinger et al., “Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomized trial”, Lancet, vol. 354, 1999, pp. 2025-2028.
Asahi Kasei Pharma Corporation
Birch & Stewart Kolasch & Birch, LLP
Emch Gregory S
Kolker Daniel E
LandOfFree
Agent for prophylaxis of reflex sympathetic dystrophy after... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agent for prophylaxis of reflex sympathetic dystrophy after..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for prophylaxis of reflex sympathetic dystrophy after... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4254278